Recursion Pharmaceuticals director undertakes share sales and conversions amid mixed clinical and financial signals
Recursion Pharmaceuticals director Christopher Gibson executed a planned sale of Class A shares that generated $164,800 and completed a Class B-to-A conversion, followed days later by a stock-based acquisition to cover tax obligations. The transactions occur against a backdrop of a 45% year-over-year share decline, weak company financial metrics, a…